Injectable dual thermoreversible hydrogel for sustained intramuscular drug delivery
Herein, we reported novel docetaxel-decorated solid lipid nanoparticle (DCT-SLN)-loaded dual thermoreversible system (DCT-DRTS) for intramuscular administration with reduced burst effect, sustained release and improved antitumor efficacy. The optimized DCT-DRTs was subjected to in-vitro and in-vivo...
Gespeichert in:
Veröffentlicht in: | Journal of controlled release 2024-10, Vol.374, p.590-605 |
---|---|
Hauptverfasser: | , , , , , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 605 |
---|---|
container_issue | |
container_start_page | 590 |
container_title | Journal of controlled release |
container_volume | 374 |
creator | Din, Fakhar Ud Kim, Jung Suk Lee, Ho Cheol Cheon, Seunghyun Woo, Mi Ran Woo, Sanghyun Ku, Sae Kwang Yoo, Hye Hyun Kim, Jong Oh Jin, Sung Giu Choi, Han-Gon |
description | Herein, we reported novel docetaxel-decorated solid lipid nanoparticle (DCT-SLN)-loaded dual thermoreversible system (DCT-DRTS) for intramuscular administration with reduced burst effect, sustained release and improved antitumor efficacy. The optimized DCT-DRTs was subjected to in-vitro and in-vivo analyses. Antitumor evaluation of the DCT-DRTS was executed and compared with DCT-hydrogel, and DCT-suspension trailed by the histopathological and immune-histochemical analyses. The DCT-SLN gave a mean particle size of 157 nm and entrapment efficiency of 93 %. It was a solid at room temperature, and changed to liquid at physiological temperature due to its melting point of about 32 °C. Unlikely, poloxamer mixture remained liquefied at 25-27 °C, however converted to gel at physiological temperature. This behavior demonstrated opposed reversible property of the DCT-SLN and poloxamer hydrogel in DCT-DRTS system, making it ideal for intramuscular administration and quick gelation inside the body. The DCT-DRTS sustained the drugs release and unlike DCT-hydrogel, the preliminary plasma concentration of DCT-DRTS was significantly reduced, overcoming the burst release. A meaningfully enhanced antitumor efficacy and improved survival rate was observed from DCT-DRTS in tumor cell xenograft athymic nude mice. Additionally, increased apoptotic and reduced proliferation markers were observed in DCT-DRTS treated tumor masses. It was concluded that DCT-DRTS may be a suitable choice for intramuscular administration of DCT with sustained release, improved bioavailability, reduced toxicity and enhanced antitumor effects.
[Display omitted]
•Docetaxel (DCT), has been used extensively for the treatment of various cancers.•We developed a novel sustained release formulation DCT-DRTS for intramuscular route.•DCT-DRTS was composed of thermosensitive solid lipid nanoparticle and hydrogel.•It demonstrated improved bioavailability, no toxicity and greater antitumor effects.•High apoptosis and reduced proliferation of tumor masses were observed in DCT-DRTS. |
doi_str_mv | 10.1016/j.jconrel.2024.08.034 |
format | Article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_3099799643</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0168365924005844</els_id><sourcerecordid>3099799643</sourcerecordid><originalsourceid>FETCH-LOGICAL-c243t-2335749f2ab81c2bce413568a8b442e82093b1d2ca3b2f4a6aee84d5c13bdc3a3</originalsourceid><addsrcrecordid>eNqFkE1LxDAQhoMoun78BKVHL61JJu0mJxHxCxY8qOeQJlNNSVtNWmH_vV129eppYHjeeZmHkHNGC0ZZddUWrR36iKHglIuCyoKC2CMLJpeQC6XKfbKYOZlDVaojcpxSSyktQSwPyREoTqWCakFenvoW7WjqgJmbTMjGD4zdEPEbY_Kb7cfaxeEdQ9YMMUtTGo3v0WW-H6PppmSnYGLm4vSeOQx-jq1PyUFjQsKz3Twhb_d3r7eP-er54en2ZpVbLmDMOUC5FKrhppbM8tqiYFBW0shaCI6SUwU1c9waqHkjTGUQpXClZVA7CwZOyOX27mccviZMo-58shiC6XGYkgaq1FKpSsCMllvUxiGliI3-jL4zca0Z1RufutU7n3rjU1OpZ59z7mJXMdUdur_Ur8AZuN4COD_67THqZD32Fp2Ps1ftBv9PxQ8miYtz</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>3099799643</pqid></control><display><type>article</type><title>Injectable dual thermoreversible hydrogel for sustained intramuscular drug delivery</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals Complete</source><creator>Din, Fakhar Ud ; Kim, Jung Suk ; Lee, Ho Cheol ; Cheon, Seunghyun ; Woo, Mi Ran ; Woo, Sanghyun ; Ku, Sae Kwang ; Yoo, Hye Hyun ; Kim, Jong Oh ; Jin, Sung Giu ; Choi, Han-Gon</creator><creatorcontrib>Din, Fakhar Ud ; Kim, Jung Suk ; Lee, Ho Cheol ; Cheon, Seunghyun ; Woo, Mi Ran ; Woo, Sanghyun ; Ku, Sae Kwang ; Yoo, Hye Hyun ; Kim, Jong Oh ; Jin, Sung Giu ; Choi, Han-Gon</creatorcontrib><description>Herein, we reported novel docetaxel-decorated solid lipid nanoparticle (DCT-SLN)-loaded dual thermoreversible system (DCT-DRTS) for intramuscular administration with reduced burst effect, sustained release and improved antitumor efficacy. The optimized DCT-DRTs was subjected to in-vitro and in-vivo analyses. Antitumor evaluation of the DCT-DRTS was executed and compared with DCT-hydrogel, and DCT-suspension trailed by the histopathological and immune-histochemical analyses. The DCT-SLN gave a mean particle size of 157 nm and entrapment efficiency of 93 %. It was a solid at room temperature, and changed to liquid at physiological temperature due to its melting point of about 32 °C. Unlikely, poloxamer mixture remained liquefied at 25-27 °C, however converted to gel at physiological temperature. This behavior demonstrated opposed reversible property of the DCT-SLN and poloxamer hydrogel in DCT-DRTS system, making it ideal for intramuscular administration and quick gelation inside the body. The DCT-DRTS sustained the drugs release and unlike DCT-hydrogel, the preliminary plasma concentration of DCT-DRTS was significantly reduced, overcoming the burst release. A meaningfully enhanced antitumor efficacy and improved survival rate was observed from DCT-DRTS in tumor cell xenograft athymic nude mice. Additionally, increased apoptotic and reduced proliferation markers were observed in DCT-DRTS treated tumor masses. It was concluded that DCT-DRTS may be a suitable choice for intramuscular administration of DCT with sustained release, improved bioavailability, reduced toxicity and enhanced antitumor effects.
[Display omitted]
•Docetaxel (DCT), has been used extensively for the treatment of various cancers.•We developed a novel sustained release formulation DCT-DRTS for intramuscular route.•DCT-DRTS was composed of thermosensitive solid lipid nanoparticle and hydrogel.•It demonstrated improved bioavailability, no toxicity and greater antitumor effects.•High apoptosis and reduced proliferation of tumor masses were observed in DCT-DRTS.</description><identifier>ISSN: 0168-3659</identifier><identifier>ISSN: 1873-4995</identifier><identifier>EISSN: 1873-4995</identifier><identifier>DOI: 10.1016/j.jconrel.2024.08.034</identifier><identifier>PMID: 39208936</identifier><language>eng</language><publisher>Netherlands: Elsevier B.V</publisher><subject><![CDATA[Animals ; Antineoplastic Agents - administration & dosage ; Antineoplastic Agents - pharmacokinetics ; Bioavailability ; Burst effect ; Cell Line, Tumor ; Delayed-Action Preparations - chemistry ; Docetaxel ; Docetaxel - administration & dosage ; Docetaxel - pharmacokinetics ; Drug Carriers - chemistry ; Drug Delivery Systems ; Drug Liberation ; Dual thermoreversible system ; Female ; Humans ; Hydrogels - administration & dosage ; Hydrogels - chemistry ; Injections, Intramuscular ; Lipids - administration & dosage ; Lipids - chemistry ; Liposomes ; Male ; Mice ; Mice, Inbred BALB C ; Mice, Nude ; Nanoparticles - administration & dosage ; Nanoparticles - chemistry ; Neoplasms - drug therapy ; Poloxamer - chemistry ; Solid lipid nanoparticles ; Sustained release ; Taxoids - administration & dosage ; Taxoids - chemistry ; Taxoids - pharmacokinetics ; Temperature ; Tumor]]></subject><ispartof>Journal of controlled release, 2024-10, Vol.374, p.590-605</ispartof><rights>2024 Elsevier B.V.</rights><rights>Copyright © 2024 Elsevier B.V. All rights reserved.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c243t-2335749f2ab81c2bce413568a8b442e82093b1d2ca3b2f4a6aee84d5c13bdc3a3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/j.jconrel.2024.08.034$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,780,784,3550,27924,27925,45995</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/39208936$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Din, Fakhar Ud</creatorcontrib><creatorcontrib>Kim, Jung Suk</creatorcontrib><creatorcontrib>Lee, Ho Cheol</creatorcontrib><creatorcontrib>Cheon, Seunghyun</creatorcontrib><creatorcontrib>Woo, Mi Ran</creatorcontrib><creatorcontrib>Woo, Sanghyun</creatorcontrib><creatorcontrib>Ku, Sae Kwang</creatorcontrib><creatorcontrib>Yoo, Hye Hyun</creatorcontrib><creatorcontrib>Kim, Jong Oh</creatorcontrib><creatorcontrib>Jin, Sung Giu</creatorcontrib><creatorcontrib>Choi, Han-Gon</creatorcontrib><title>Injectable dual thermoreversible hydrogel for sustained intramuscular drug delivery</title><title>Journal of controlled release</title><addtitle>J Control Release</addtitle><description>Herein, we reported novel docetaxel-decorated solid lipid nanoparticle (DCT-SLN)-loaded dual thermoreversible system (DCT-DRTS) for intramuscular administration with reduced burst effect, sustained release and improved antitumor efficacy. The optimized DCT-DRTs was subjected to in-vitro and in-vivo analyses. Antitumor evaluation of the DCT-DRTS was executed and compared with DCT-hydrogel, and DCT-suspension trailed by the histopathological and immune-histochemical analyses. The DCT-SLN gave a mean particle size of 157 nm and entrapment efficiency of 93 %. It was a solid at room temperature, and changed to liquid at physiological temperature due to its melting point of about 32 °C. Unlikely, poloxamer mixture remained liquefied at 25-27 °C, however converted to gel at physiological temperature. This behavior demonstrated opposed reversible property of the DCT-SLN and poloxamer hydrogel in DCT-DRTS system, making it ideal for intramuscular administration and quick gelation inside the body. The DCT-DRTS sustained the drugs release and unlike DCT-hydrogel, the preliminary plasma concentration of DCT-DRTS was significantly reduced, overcoming the burst release. A meaningfully enhanced antitumor efficacy and improved survival rate was observed from DCT-DRTS in tumor cell xenograft athymic nude mice. Additionally, increased apoptotic and reduced proliferation markers were observed in DCT-DRTS treated tumor masses. It was concluded that DCT-DRTS may be a suitable choice for intramuscular administration of DCT with sustained release, improved bioavailability, reduced toxicity and enhanced antitumor effects.
[Display omitted]
•Docetaxel (DCT), has been used extensively for the treatment of various cancers.•We developed a novel sustained release formulation DCT-DRTS for intramuscular route.•DCT-DRTS was composed of thermosensitive solid lipid nanoparticle and hydrogel.•It demonstrated improved bioavailability, no toxicity and greater antitumor effects.•High apoptosis and reduced proliferation of tumor masses were observed in DCT-DRTS.</description><subject>Animals</subject><subject>Antineoplastic Agents - administration & dosage</subject><subject>Antineoplastic Agents - pharmacokinetics</subject><subject>Bioavailability</subject><subject>Burst effect</subject><subject>Cell Line, Tumor</subject><subject>Delayed-Action Preparations - chemistry</subject><subject>Docetaxel</subject><subject>Docetaxel - administration & dosage</subject><subject>Docetaxel - pharmacokinetics</subject><subject>Drug Carriers - chemistry</subject><subject>Drug Delivery Systems</subject><subject>Drug Liberation</subject><subject>Dual thermoreversible system</subject><subject>Female</subject><subject>Humans</subject><subject>Hydrogels - administration & dosage</subject><subject>Hydrogels - chemistry</subject><subject>Injections, Intramuscular</subject><subject>Lipids - administration & dosage</subject><subject>Lipids - chemistry</subject><subject>Liposomes</subject><subject>Male</subject><subject>Mice</subject><subject>Mice, Inbred BALB C</subject><subject>Mice, Nude</subject><subject>Nanoparticles - administration & dosage</subject><subject>Nanoparticles - chemistry</subject><subject>Neoplasms - drug therapy</subject><subject>Poloxamer - chemistry</subject><subject>Solid lipid nanoparticles</subject><subject>Sustained release</subject><subject>Taxoids - administration & dosage</subject><subject>Taxoids - chemistry</subject><subject>Taxoids - pharmacokinetics</subject><subject>Temperature</subject><subject>Tumor</subject><issn>0168-3659</issn><issn>1873-4995</issn><issn>1873-4995</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2024</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkE1LxDAQhoMoun78BKVHL61JJu0mJxHxCxY8qOeQJlNNSVtNWmH_vV129eppYHjeeZmHkHNGC0ZZddUWrR36iKHglIuCyoKC2CMLJpeQC6XKfbKYOZlDVaojcpxSSyktQSwPyREoTqWCakFenvoW7WjqgJmbTMjGD4zdEPEbY_Kb7cfaxeEdQ9YMMUtTGo3v0WW-H6PppmSnYGLm4vSeOQx-jq1PyUFjQsKz3Twhb_d3r7eP-er54en2ZpVbLmDMOUC5FKrhppbM8tqiYFBW0shaCI6SUwU1c9waqHkjTGUQpXClZVA7CwZOyOX27mccviZMo-58shiC6XGYkgaq1FKpSsCMllvUxiGliI3-jL4zca0Z1RufutU7n3rjU1OpZ59z7mJXMdUdur_Ur8AZuN4COD_67THqZD32Fp2Ps1ftBv9PxQ8miYtz</recordid><startdate>202410</startdate><enddate>202410</enddate><creator>Din, Fakhar Ud</creator><creator>Kim, Jung Suk</creator><creator>Lee, Ho Cheol</creator><creator>Cheon, Seunghyun</creator><creator>Woo, Mi Ran</creator><creator>Woo, Sanghyun</creator><creator>Ku, Sae Kwang</creator><creator>Yoo, Hye Hyun</creator><creator>Kim, Jong Oh</creator><creator>Jin, Sung Giu</creator><creator>Choi, Han-Gon</creator><general>Elsevier B.V</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>202410</creationdate><title>Injectable dual thermoreversible hydrogel for sustained intramuscular drug delivery</title><author>Din, Fakhar Ud ; Kim, Jung Suk ; Lee, Ho Cheol ; Cheon, Seunghyun ; Woo, Mi Ran ; Woo, Sanghyun ; Ku, Sae Kwang ; Yoo, Hye Hyun ; Kim, Jong Oh ; Jin, Sung Giu ; Choi, Han-Gon</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c243t-2335749f2ab81c2bce413568a8b442e82093b1d2ca3b2f4a6aee84d5c13bdc3a3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2024</creationdate><topic>Animals</topic><topic>Antineoplastic Agents - administration & dosage</topic><topic>Antineoplastic Agents - pharmacokinetics</topic><topic>Bioavailability</topic><topic>Burst effect</topic><topic>Cell Line, Tumor</topic><topic>Delayed-Action Preparations - chemistry</topic><topic>Docetaxel</topic><topic>Docetaxel - administration & dosage</topic><topic>Docetaxel - pharmacokinetics</topic><topic>Drug Carriers - chemistry</topic><topic>Drug Delivery Systems</topic><topic>Drug Liberation</topic><topic>Dual thermoreversible system</topic><topic>Female</topic><topic>Humans</topic><topic>Hydrogels - administration & dosage</topic><topic>Hydrogels - chemistry</topic><topic>Injections, Intramuscular</topic><topic>Lipids - administration & dosage</topic><topic>Lipids - chemistry</topic><topic>Liposomes</topic><topic>Male</topic><topic>Mice</topic><topic>Mice, Inbred BALB C</topic><topic>Mice, Nude</topic><topic>Nanoparticles - administration & dosage</topic><topic>Nanoparticles - chemistry</topic><topic>Neoplasms - drug therapy</topic><topic>Poloxamer - chemistry</topic><topic>Solid lipid nanoparticles</topic><topic>Sustained release</topic><topic>Taxoids - administration & dosage</topic><topic>Taxoids - chemistry</topic><topic>Taxoids - pharmacokinetics</topic><topic>Temperature</topic><topic>Tumor</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Din, Fakhar Ud</creatorcontrib><creatorcontrib>Kim, Jung Suk</creatorcontrib><creatorcontrib>Lee, Ho Cheol</creatorcontrib><creatorcontrib>Cheon, Seunghyun</creatorcontrib><creatorcontrib>Woo, Mi Ran</creatorcontrib><creatorcontrib>Woo, Sanghyun</creatorcontrib><creatorcontrib>Ku, Sae Kwang</creatorcontrib><creatorcontrib>Yoo, Hye Hyun</creatorcontrib><creatorcontrib>Kim, Jong Oh</creatorcontrib><creatorcontrib>Jin, Sung Giu</creatorcontrib><creatorcontrib>Choi, Han-Gon</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Journal of controlled release</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Din, Fakhar Ud</au><au>Kim, Jung Suk</au><au>Lee, Ho Cheol</au><au>Cheon, Seunghyun</au><au>Woo, Mi Ran</au><au>Woo, Sanghyun</au><au>Ku, Sae Kwang</au><au>Yoo, Hye Hyun</au><au>Kim, Jong Oh</au><au>Jin, Sung Giu</au><au>Choi, Han-Gon</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Injectable dual thermoreversible hydrogel for sustained intramuscular drug delivery</atitle><jtitle>Journal of controlled release</jtitle><addtitle>J Control Release</addtitle><date>2024-10</date><risdate>2024</risdate><volume>374</volume><spage>590</spage><epage>605</epage><pages>590-605</pages><issn>0168-3659</issn><issn>1873-4995</issn><eissn>1873-4995</eissn><abstract>Herein, we reported novel docetaxel-decorated solid lipid nanoparticle (DCT-SLN)-loaded dual thermoreversible system (DCT-DRTS) for intramuscular administration with reduced burst effect, sustained release and improved antitumor efficacy. The optimized DCT-DRTs was subjected to in-vitro and in-vivo analyses. Antitumor evaluation of the DCT-DRTS was executed and compared with DCT-hydrogel, and DCT-suspension trailed by the histopathological and immune-histochemical analyses. The DCT-SLN gave a mean particle size of 157 nm and entrapment efficiency of 93 %. It was a solid at room temperature, and changed to liquid at physiological temperature due to its melting point of about 32 °C. Unlikely, poloxamer mixture remained liquefied at 25-27 °C, however converted to gel at physiological temperature. This behavior demonstrated opposed reversible property of the DCT-SLN and poloxamer hydrogel in DCT-DRTS system, making it ideal for intramuscular administration and quick gelation inside the body. The DCT-DRTS sustained the drugs release and unlike DCT-hydrogel, the preliminary plasma concentration of DCT-DRTS was significantly reduced, overcoming the burst release. A meaningfully enhanced antitumor efficacy and improved survival rate was observed from DCT-DRTS in tumor cell xenograft athymic nude mice. Additionally, increased apoptotic and reduced proliferation markers were observed in DCT-DRTS treated tumor masses. It was concluded that DCT-DRTS may be a suitable choice for intramuscular administration of DCT with sustained release, improved bioavailability, reduced toxicity and enhanced antitumor effects.
[Display omitted]
•Docetaxel (DCT), has been used extensively for the treatment of various cancers.•We developed a novel sustained release formulation DCT-DRTS for intramuscular route.•DCT-DRTS was composed of thermosensitive solid lipid nanoparticle and hydrogel.•It demonstrated improved bioavailability, no toxicity and greater antitumor effects.•High apoptosis and reduced proliferation of tumor masses were observed in DCT-DRTS.</abstract><cop>Netherlands</cop><pub>Elsevier B.V</pub><pmid>39208936</pmid><doi>10.1016/j.jconrel.2024.08.034</doi><tpages>16</tpages></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0168-3659 |
ispartof | Journal of controlled release, 2024-10, Vol.374, p.590-605 |
issn | 0168-3659 1873-4995 1873-4995 |
language | eng |
recordid | cdi_proquest_miscellaneous_3099799643 |
source | MEDLINE; Elsevier ScienceDirect Journals Complete |
subjects | Animals Antineoplastic Agents - administration & dosage Antineoplastic Agents - pharmacokinetics Bioavailability Burst effect Cell Line, Tumor Delayed-Action Preparations - chemistry Docetaxel Docetaxel - administration & dosage Docetaxel - pharmacokinetics Drug Carriers - chemistry Drug Delivery Systems Drug Liberation Dual thermoreversible system Female Humans Hydrogels - administration & dosage Hydrogels - chemistry Injections, Intramuscular Lipids - administration & dosage Lipids - chemistry Liposomes Male Mice Mice, Inbred BALB C Mice, Nude Nanoparticles - administration & dosage Nanoparticles - chemistry Neoplasms - drug therapy Poloxamer - chemistry Solid lipid nanoparticles Sustained release Taxoids - administration & dosage Taxoids - chemistry Taxoids - pharmacokinetics Temperature Tumor |
title | Injectable dual thermoreversible hydrogel for sustained intramuscular drug delivery |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-04T10%3A20%3A21IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Injectable%20dual%20thermoreversible%20hydrogel%20for%20sustained%20intramuscular%20drug%20delivery&rft.jtitle=Journal%20of%20controlled%20release&rft.au=Din,%20Fakhar%20Ud&rft.date=2024-10&rft.volume=374&rft.spage=590&rft.epage=605&rft.pages=590-605&rft.issn=0168-3659&rft.eissn=1873-4995&rft_id=info:doi/10.1016/j.jconrel.2024.08.034&rft_dat=%3Cproquest_cross%3E3099799643%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=3099799643&rft_id=info:pmid/39208936&rft_els_id=S0168365924005844&rfr_iscdi=true |